 |
Previous Article | Next Article 
Volume 16, Number 18,
Issue of September 15, 1996
pp. 5741-5748
Copyright ©1996 Society for Neuroscience
Modulation of the Inhibitory Substrate Properties of
Oligodendrocytes by Platelet-Derived Growth Factor
Dirk M. Lang1,
Michael
G. Hille1,
Martin E. Schwab2, and
Claudia A. O. Stuermer1
1 Faculty of Biology, University of Konstanz, D-78434
Konstanz, Germany, and 2 Institute for Brain Research,
University of Zürich, CH-8029 Zürich, Switzerland
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES
ABSTRACT
Although growth cones typically collapse after encountering
O1/galactocerebroside (GalC)-positive oligodendrocytes, the majority of
growth cones traversed oligodendrocytes, which were raised for 8-10 d
in medium containing 10 ng/ml platelet-derived growth factor (PDGF).
Oligodendrocytes raised 8-10 d in control medium caused growth cone
collapse as they normally do, but failed to elicit this response after
being transferred to PDGF-containing medium for an additional 8-10 d.
The opposite was observed when PDGF-treated oligodendrocytes were
brought to control medium. Growth cones collapsed when contacting these
cells. Oligodendrocytes also lost their collapse-inducing activity when
raised in medium conditioned by astrocytes, known to produce PDGF.
Antibody IN-1 is directed against neurite growth inhibitors (NI),
proteins of 35 and 250 kDa on the surface of O1/GalC-positive
oligodendrocytes, which are known to elicit growth cone collapse. IN-1
immunoreactivity was markedly reduced in PDGF-treated oligodendrocytes.
However, both PDGF-treated and control oligodendrocytes exhibited
myelin-associated glycoprotein, proteolipid protein, and myelin basic
protein immunoreactivity. This suggests that PDGF-treatment affects NI
expression but does not interfere with the expression of advanced
myelin marker proteins. Because NI cause growth cone collapse, the loss
of collapse-inducing activity by PDGF-treated oligodendrocytes suggests
that PDGF regulates, directly or indirectly, the expression of these
proteins.
Key words:
oligodendrocyte;
loss of inhibitory
properties;
PDGF-treatment;
growth cone collapse;
IN-1
immunoreactivity;
astrocyte-conditioned medium
INTRODUCTION
Neurite growth inhibitors (NI) elicit collapse of
growth cones and retraction of axons in vitro and impair the
regrowth of injured CNS fiber tracts in vivo (Schwab et al.,
1993 ). These inhibitors are found on the surface of oligodendrocytes
and CNS myelin and are proteins of 35 and 250 kDa (Caroni and Schwab,
1988a ; Schwab and Caroni, 1988 ). Strategies for enhancing axonal
regeneration, therefore, involve overcoming the inhibitors' action or,
if possible, hindering their expression.
The first approach has been successful: the action of the inhibitors
can be partially neutralized in vitro (Caroni and Schwab,
1988b ) and in vivo (Schnell et al., 1994 ) by applications of
the antibody IN-1. Because the myelin-associated NI are not yet cloned,
the pathways regulating their expression are still unknown. Also, the
onset of expression is not precisely defined. Nevertheless, it has been
noted that oligodendrocytes in vitro expressing the
differentiation marker galactocerebroside (GalC) and exhibiting a
highly branched morphology (Schwab and Caroni, 1988 ) have acquired
inhibitory properties, as judged from growth cone reactions after
contact with oligodendrocytes (Fawcett et al., 1989 ; Bandtlow et
al., 1990 ; Bastmeyer et al., 1991 ).
During further differentiation, oligodendrocytes express additional
proteins, including proteolipid protein (PLP), myelin basic protein
(MBP), and myelin-associated glycoprotein (MAG), all of which
contribute to the formation of proper myelin sheath. MAG has recently
been discussed as another inhibitor of axon growth (McKerracher et al.,
1994 ; Mukhopadhyay et al., 1994 ).
Oligodendrocytes develop from O-2A progenitor cells under the influence
of a variety of growth factors (Raff et al., 1983 ). Some, such as
interleukin-6 (Il-6), ciliary neurotrophic factor (CNTF), and
insulin-like growth factor (IGF), enhance oligodendrocyte
differentiation and promote their survival (Barres et al., 1993 ).
Platelet-derived growth factor (PDGF), another important growth factor
with three subtypes (PDGF-AA, PDGF-AB, and PDGF-BB) (Heldin et al.,
1988 ), stimulates proliferation of O-2A progenitors (Noble et al.,
1988 ; Richardson et al., 1988 ), positively influences their survival
(Barres et al., 1993 ), and contributes to the expression of myelin
proteins (Grinspan et al., 1993 ).
An additional, unexpected function of PDGF that affects the inhibitory
properties of oligodendrocytes during their differentiation in
vitro is described here. Oligodendrocytes that remained in medium
containing PDGF-AB for more than 1 week lost their inhibitory influence
on growth cones. Moreover, IN-1 immunoreactivity was significantly
reduced in PDGF-treated oligodendrocytes, whereas expression of
O1/GalC, MBP, PLP, and MAG remained unchanged as judged from
immunostaining experiments with the relevant antibodies.
Oligodendrocytes regained their inhibitory influence when deprived of
PDGF-AB. Thus, PDGF-AB appears to regulate directly or indirectly the
expression of the NI.
MATERIALS AND METHODS
Primary cultures from rat optic nerves. Mixed glial
cultures from optic nerves of 7- to 10-d-old rats were prepared as
described (Schwab and Caroni, 1988 ). Cells were plated onto
polylysine/laminin-coated coverslips at low density (~1000
cells/cm2) and kept for 8-10 d in either Dulbecco's
minimal essential medium (DMEM) or in DMEM/Ham's F12 (1:1). Both media
contained 10 µg/ml bovine serum albumin, 10 µg/ml human
transferrin, 5 µg/ml bovine insulin, 20 n progesterone,
30 n Na-selenite, 100 µ putrescine, 15 n tri-iodothyronine, 2 m glutamine, 1 m Na-pyruvate, 0.4% methyl cellulose (MC), and 50 µg/ml
gentamycin. Three times a week half of the medium was changed.
Recombinant PDGF (PDGF-AB; Sigma, Deisenhofen, Germany or Biomol,
Hamburg, Germany; 10 ng/ml) was added to the cultures three times a
week.
Secondary cultures enriched in oligodendrocytes and astrocytes.
Mixed glial cultures were prepared by mechanical dissociation of
cerebral cortices of neonatal rat pups. Cells were grown to confluency
in DMEM containing 10% fetal calf serum (FCS) in polylysine-coated
tissue culture flasks. Oligodendrocytes were collected according to
methods described earlier (McCarthy and De Vellis, 1980 ) and replated
onto polylysine/laminin-coated coverslips at a density of ~1000
cells/cm2 in defined DMEM or DMEM/F12 medium with
supplements, described above.
Cultures from which most of the oligodendrocytes were removed, (and
which were thus enriched in astrocytes) were used to collect
astrocyte-conditioned serum-free medium. This medium was applied to
oligodendrocytes in one experiment instead of PDGF.
Cocultures of oligodendrocytes and neuronal explants. Dorsal
root ganglia (DRGs) from neonatal rats were chopped into small
segments, resuspended in DMEM/F12 containing 100 ng/ml nerve growth
factor (NGF) and 0.4% MC, and added to glial cultures that had been
rinsed three times in PDGF-free culture medium before the addition of
DRGs. Cocultures in Petriperm dishes (Heraeus, Hanau, Germany) were
incubated in a small volume of medium overnight for DRG attachment and
neurite outgrowth. These cultures were used either for time-lapse
videomicroscopy, or, after an incubation period of 2 d, subjected
to a double immunostaining procedure to visualize oligodendrocytes and
to identify DRG neurites.
In some experiments, the antimitotic drug cytosine arabinofuranoside
(AraC; Sigma) was added (8 µ) to glial cultures for at
least 3 d before the addition of DRG explants to prevent the
emergence of new (immature) oligodendrocytes from progenitor cells and
to suppress astrocyte proliferation.
Explants of goldfish and Xenopus retinae were obtained from
adult animals that had received optic nerve cuts 10-14 d before
preparation. The retinae were attached to nylon filters, cut into 300 µm wide stripes, and placed, ganglion cell layer down, onto the
coverslips carrying the glial cells. Cocultures were maintained
overnight at 28°C, a compromise temperature that allows survival of
rat oligodendrocytes and outgrowth of fish and amphibian axons
(Bastmeyer et al., 1993 ; Lang et al., 1995 ).
Time-lapse videomicroscopy. Cocultures of glial cells and
neuronal explants were transferred to DMEM/F12 containing 100 ng/ml
NGF, 0.4% MC, and 15 m HEPES buffer (instead of
bicarbonate) and left to equilibrate for 1 hour on the heatable stage
of an inverted microscope (Zeiss, Oberkochen, Germany). Cocultures with
rat DRGs were kept at 37°C. For the cocultures with fish and
amphibian axons, stage temperature was reduced to 28°C. Time-lapse
sequences of axons encountering oligodendrocytes were videotaped over
12-16 hr. At least three cocultures were examined in each experiment.
Only those oligodendrocytes that displayed a highly branched morphology
indicating complete differentiation were chosen for the recordings. In
most cases, living oligodendrocytes were stained with monoclonal
antibodies (mAbs) O1 (Sommer and Schachner, 1981 ) or anti-GalC (Ranscht
et al., 1982 ) before the time-lapse recordings to facilitate
identification of differentiated cells.
Immunofluorescence and quantification of staining
intensity. Monoclonal antibody (mAb) A2B5, a marker for O-2A
progenitor cells (Raff et al., 1983 ), and mAbs anti-GalC and O1,
markers for differentiated oligodendrocytes (Sommer and Schachner,
1981 ; Ranscht et al., 1982 ), were applied to live cells as described
(Bastmeyer et al., 1991 ). Cocultures of oligodendrocytes and DRG
neurons were double-labeled with mAb O1 and a rabbit antiserum to the
cell adhesion molecule L1 (gift of F. Rathjen, MDC, Berlin,
Germany). To detect NI on the cell surface, live oligodendrocytes
were incubated (2 hr; 37°C) with undiluted hybridoma supernatant
containing mAb IN-1 (Caroni and Schwab, 1988b ). For detection of myelin
markers expressed by oligodendrocytes, double and triple fluorescence
labeling was performed with an mAb against MBP (dilution 1:10), a
rabbit antiserum against PLP (dilution 1:200; both gifts of C. Linington, MPJ, Munich, Germany), and a rabbit antiserum to MAG
(dilution 1:200; gift of M. Schachner, ETH, Zürich, Switzerland)
after fixation in methanol (5 min; 20°C) and 4% paraformaldehyde
(5 min; room temperature). In some cases, for exclusive labeling of MAG
expressed on the cell surface, live oligodendrocytes were incubated
with the antiserum (1 hr; 37°C). Secondary antibodies were goat
anti-mouse 7-amino-4-methylcoumarin-3-acetate, goat anti-rat
tetramethylrhodamine-isothiocyanate (TRITC), and goat anti-rabbit TRITC
or fluorescein-isothiocyanate (all from Dianova, Hamburg, Germany;
dilution 1:200). For visualization of bound IN-1 antibodies,
µ-chain-specific donkey or rat anti-mouse cyanin-3 (Cy-3; Dianova;
dilution 1:1000) was used.
The intensity of immunofluorescence was quantified in oligodendrocytes
double-labeled with mAb IN-1 against NI and anti-PLP or anti-MAG to see
whether the PDGF-induced reduction of inhibitory substrate properties
is paralleled by a reduction of IN-1 immunoreactivity. Fluorescence
values were measured in the flat membraneous extensions typical of
differentiated oligodendrocytes, which were visualized by PLP or MAG
immunoreactivity. The staining procedure with the Cy-3-conjugated
secondary antibody produced nonspecific fluorescence in the soma but
not on the membranous extensions (see Fig. 7).
Fig. 7.
Comparison of labeling intensity in
oligodendrocytes exposed to mAb IN-1 (a) and anti-PLP
(b). Measurements were taken in membrane sheets of
double-labeled oligodendrocytes from control (black
bars) and PDGF-treated cultures (white bars).
Hatched bars in a represent background
staining on the membraneous extensions of oligodendrocytes generated by
the secondary Cy-3-conjugated antibody alone. The insert
in a represents intensity measurements (in percentage)
of the somata. Black bar in insert
represents somata of control oligodendrocytes; white
bar, PDGF-treated oligodendrocytes (100%); hatched
bar, Cy-3-conjugated antibody alone. Intensity units were
generated by the image processing system. On average, IN-1 labeling in
membrane sheets is decreased by 70% in PDGF-treated oligodendrocytes,
whereas PLP labeling remains constant or increases. Note that the
intensity of anti-PLP staining is approximately 10 times that of mAb
IN-1.
[View Larger Version of this Image (30K GIF file)]
Moreover, when the intensity measurements were adapted to the weak
immunofluorescence signals obtained with IN-1 and secondary antibody,
the soma of the oligodendrocytes produced a signal even when no
antibody was applied. This signal from the soma was increased when
cells were subjected to staining with Cy-3-conjugated secondary
antibody alone (see Fig. 7). Therefore, control experiments were
performed in which PDGF-treated and -untreated oligodendrocytes
(n = 12 each) were subjected to the same
immunofluorescence intensity measurements after exposure to
Cy-3-conjugated secondary antibody alone. More than 80% of the
immunofluorescence of the somata turned out to be unspecific.
Therefore, cell bodies of oligodendrocytes were not included in the
evaluation.
The level of unspecific Cy-3 fluorescence intensity on the membraneous
extensions, however, was insignificant compared with that produced by
primary and secondary antibodies (see Fig. 7). In each measurement, the
fluorescence intensity was averaged over a membrane area between 25 and
300 µm2. Six measurements were made per oligodendrocyte,
and values were obtained from 12 cells in each experimental group (see
Fig. 7) representing one set. Three sets of experiments, including
controls, were performed, two sets with anti-PLP as reference and one
set with anti-MAG. Figure 7 represents the results of one set.
Fluorescence images and measurements were taken with an ICCD camera
(Hamamatsu, Herrsching, Germany) and quantified using the image
processing system HPD-CPx (Hamamatsu) equipped with the Argus
software.
To detect glial cells undergoing DNA replication, cultures were
incubated in medium with 10 µ bromodeoxyuridine (BrdU;
Sigma). Twenty-four hours later, the live cultures were stained with
mAb 01, exposed to goat anti-mouse TRITC and subsequently processed for
anti-BrdU immunohistochemistry as described elsewhere (Nowakowski et
al., 1989 ).
RESULTS
PDGF-induced reduction of inhibitory properties
of oligodendrocytes
Control and experimental glial cell cultures were maintained 8-10
d in medium known to enhance oligodendrocyte differentiation (Raff et
al., 1985 ; Noble et al., 1988 ; Grinspan et al., 1993 ), but only the
experimental cultures received PDGF. In both cultures, the majority of
cells acquired a highly branched morphology typical of differentiated
oligodendrocytes (Fig. 1). As expected, these were more
numerous in the PDGF-treated cultures than in controls (Noble et al.,
1988 ; Richardson et al., 1988 ).
Fig. 1.
Cocultures of oligodendrocytes and DRG neurons
double-stained with anti-L1 (a, c) and O1
(b, d). DRG neurites in PDGF-free control
medium avoid crossing the oligodendrocytes (a,
b). PDGF-treated oligodendrocytes, however, are freely
crossed by the neurites (c, d). Scale
bar, 50 µm.
[View Larger Version of this Image (137K GIF file)]
Retina explants or DRGs were cocultured with oligodendrocytes. In
control cultures, the vast majority of axons extending from the
neuronal tissue avoided crossing the oligodendrocytes (Fig. 1). This is
typical for most neurons tested so far (Fawcett et al., 1989 ; Bandtlow
et al., 1990 ; Bastmeyer et al., 1991 ; Lang et al., 1995 ) and is
indicative of the inhibitory properties of differentiated rat
oligodendrocytes. However, in PDGF-containing cultures the opposite was
observed. The majority of axons grew over the oligodendrocytes (Fig.
1).
To examine the reaction of individual growth cones when they contact
these oligodendrocytes, their encounters were monitored with time-lapse
video recordings. With DRGs added to 8- to 10-d-old control cultures,
27 of 34 contacts resulted in growth cone collapse and subsequent
axonal retraction; seven growth cones avoided the oligodendrocytes by
growing around the cells (Fig. 2). In contrast, the
majority of oligodendrocytes raised in PDGF-containing medium for 8-10
d (henceforth called PDGF-treated oligodendrocytes) failed to induce
DRG growth cone collapse (Fig. 2). In 32 of 49 encounters, growth cones
managed to cross the oligodendrocytes. Only nine resulted in growth
cone collapse, and in eight events axons grew around the cells (Fig.
2). All examined oligodendrocytes exhibited a highly branched
morphology and were O1-positive, like their untreated counterparts
(Fig. 3).
Fig. 2.
Quantification (in percentage) of DRG growth cone
reactions after contacting oligodendrocytes. Black bars
represent collapse, hatched bars growth around the cell,
and white bars growth across the cell. Numbers of growth
cones are given on top of each bar. Oligodendrocytes
were derived from the optic nerve and cortex, respectively, and raised
over 8-10 d in medium without PDGF (ON,
CX) or in medium with PDGF (ON+PDGF,
CX+PDGF) before the addition of DRG neurons.
[View Larger Version of this Image (25K GIF file)]
Fig. 3.
Selected images of time-lapse movies illustrating
the response of growth cones after encountering PDGF-treated
oligodendrocytes, which are O1-positive (c,
f, i). a, b, DRG growth
cones. d, e, Xenopus retinal growth
cones. g, h, Goldfish retinal growth cones. Growth cones
(marked by arrowheads) cross the oligodendrocytes. Scale
bar, 100 µm.
[View Larger Version of this Image (170K GIF file)]
A similar change in growth cone behavior was seen when fish and
Xenopus retinal axons were confronted with PDGF-treated
oligodendrocytes (Fig. 3). In control cultures, most growth cones of
both fish (Bastmeyer et al., 1991 ) and Xenopus retinae
collapse after contact with rat oligodendrocytes. With PDGF-treated
oligodendrocytes, however, the majority of Xenopus as well
as goldfish retinal axons crossed the cells (Fig. 3). Again, both
PDGF-treated oligodendrocytes and oligodendrocytes in control cultures
were positive for O1 and GalC, respectively.
In summary, the majority of growth cones of all three neuron types
collapse in contact with oligodendrocytes of control cultures but cross
PDGF-treated oligodendrocytes. This suggests that the 8-10 d exposure
to PDGF alters the inhibitory substrate properties of
oligodendrocytes.
To determine whether oligodendrocytes from other areas of the CNS
similarly fail to elicit growth cone collapse when treated with PDGF,
glial cells were obtained from rat cortices. Again, cultures were
raised for 8-10 d one group maintained in medium with PDGF, the
control group in medium without PDGF.
Oligodendrocytes in control cultures elicited DRG growth cone
collapse in 14 of 18 encounters (Fig. 2). One growth cone grew onto an
oligodendrocyte but collapsed after a few minutes and retracted. Three
growth cones avoided the oligodendrocytes. PDGF-treated
oligodendrocytes, however, were crossed by growth cones in the majority
of cases, i.e., in 20 of 27 (Fig. 2). Only three growth cones avoided
the oligodendrocytes and four collapsed. In two instances, growth cones
extended for considerable distance onto an oligodendrocyte, but then
collapsed and retracted.
PDGF is known to be mitogenic for oligodendrocyte precursor cells
(Noble et al., 1988 ; Richardson et al., 1988 ). To exclude the
possibility that PDGF-treated cultures might contain large numbers of
newly differentiated oligodendrocytes, which may not yet have acquired
their inhibitory substrate properties, the oligodendrocyte cultures
received the anti-mitotic drug AraC. AraC was added to cultures that
grew in the absence or presence of PDGF, and was present for at least
3 d before addition of neuronal explants.
This procedure resulted in the elimination of proliferating cells but
left behind the differentiated, highly branched O1/GalC-positive
oligodendrocytes. The efficiency of the AraC treatment was evaluated by
BrdU incorporation assays in parallel cultures, which were devoid of
BrdU-labeled cells. In cocultures with DRG neurons, the numbers of
oligodendrocytes from AraC/PDGF-treated cultures, which were avoided or
overgrown by neurites, were counted (Fig. 4) and
compared with cocultures with AraC-treated oligodendrocytes not having
received PDGF. In PDGF-treated cultures, >80% of the oligodendrocytes
were overgrown by DRG neurites, and the majority (70%) of cells were
avoided in the controls. This is consistent with the outcome of the
time-lapse experiments (Fig. 2).
Fig. 4.
Percentage of AraC-treated oligodendrocytes
cultured in the absence (w/o PDGF) or presence of PDGF
(with PDGF) that were avoided (black
bars) or crossed (white bars) by DRG neurites.
The number of cells is indicated on top of
each bar.
[View Larger Version of this Image (17K GIF file)]
Expression of advanced myelin marker proteins and IN-1
immunoreactivity by PDGF-treated oligodendrocytes
Although the substrate properties of O1/GalC-positive highly
branched oligodendrocytes in PDGF-treated oligodendrocytes differed
from those of oligodendrocytes in untreated cultures, the proportion of
O1/GalC-positive cells was identical in both cultures. More than 90%
of the highly branched oligodendrocytes expressed O1/GalC after 8-10
d, in PDGF-treated as well as in untreated cultures. Oligodendrocytes
of both groups were negative for the early differentiation marker A2B5
(Raff et al., 1983 ). Furthermore, O1/GalC-positive oligodendrocytes did
not incorporate BrdU, either in cultures treated with PDGF or in
untreated cultures. Moreover, when exposed to antibodies against
advanced myelin markers (MBP, PLP, MAG), highly branched
oligodendrocytes also exhibited MBP and PLP immunoreactivity, whether
raised with PDGF or without (Fig. 5).
Fig. 5.
Oligodendrocytes whether raised in medium with
(a, c, e,
g) or without (b, d,
f, h) PDGF, are immunopositive after
exposure to mAb O1 (a, b), anti-MBP
(c, d), anti-PLP (e,
f), and anti-MAG (g,
h). Scale bars: 50 µm in
a-f; 100 µm in g and
h.
[View Larger Version of this Image (116K GIF file)]
These oligodendrocytes also possessed intense MAG immunoreactivity.
This is interesting because MAG was recently described as being
inhibitory to adult DRGs and other axons (McKerracher et al., 1994 ;
Mukhopadhyay et al., 1994 ). But here, with MAG present on PDGF-treated
oligodendrocytes, all three types of growth cones grew, in the majority
of cases (Fig. 2, 3), across the cells.
Using a highly sensitive detection method with Cy-3-conjugated
secondary antibodies in conjunction with a computer-assisted
quantification procedure, the intensity of IN-1 immunoreactivity in
membraneous extensions of highly branched oligodendrocytes was
measured. Three independent sets of experiments, including the
appropriate controls (see Materials and Methods) were performed, and
all three gave similar results. The outcome of one set is shown in
Figure 7. The intensity of IN-1 immunofluorescence was reduced in
PDGF-treated oligodendrocytes, representing ~30% of that seen in
untreated control cultures (Fig. 6, 7).
These oligodendrocytes, PDGF-treated and controls, were double-stained
with antibodies against PLP or MAG. PLP immunoreactivity was strong in
both sets of oligodendrocytes and appeared slightly increased in the
PDGF-treated cells. The same applied to MAG immunoreactivity (not
shown). Furthermore, there was no direct correlation between the
intensities of IN-1 and PLP immunofluorescence for individual
oligodendrocytes (correlation coefficient r = 0.04 and
0.11 for PDGF-treated and untreated cells, respectively). The same
measurements performed on cortical oligodendrocytes yielded identical
results (not shown).
Fig. 6.
Double labeling of oligodendrocytes with anti-PLP
(A, C) and mAb IN-1 (B,
D). In both PDGF-treated (C,
D) and control cultures (A,
B), oligodendrocytes possess membraneous extensions with
intense PLP immunoreactivity. IN-1 immunoreactivity, although readily
detectable in membraneous extensions of untreated oligodendrocytes
(B), is weak in PDGF-treated cells
(D) and basically absent from their membraneous
extensions. More than 80% of staining on the soma results from the
secondary Cy-3-conjugated antibody alone. Images of IN-1-immunoreactive
oligodendrocytes are enhanced. Scale bar, 50 µm.
[View Larger Version of this Image (130K GIF file)]
These data show that PDGF treatment of oligodendrocytes does not change
the expression of advanced myelin marker proteins, and thus does not
prevent their normal in vitro differentiation. However, PDGF
does influence and reduces IN-1 immunoreactivity and the inhibitory
properties of oligodendrocytes, most likely by downregulating the
production or expression of NI on the oligodendrocyte's surface.
The effect of PDGF on substrate properties of oligodendrocytes
is reversible
Whether exposure to PDGF could change the substrate properties of
oligodendrocytes that had already become inhibitory was tested in a
further group of experiments.
As demonstrated earlier and confirmed here, virtually all
oligodendrocytes in control medium differentiated and had inhibitory
substrate properties (Figs. 1, 2). However, when these oligodendrocytes
were then exposed to medium with PDGF for another week, most of them
became growth-permissive (Fig. 8). This was concluded
from the behavior of DRGs that were added to the culture at this time.
Of the 22 encounters between oligodendrocytes and DRG growth cones
observed here, only four resulted in growth cone collapse. Three axons
avoided the oligodendrocytes, but 15 traversed the cells. Thus, it
appears that oligodendrocytes that had acquired inhibitory substrate
properties lose them again through the influence of PDGF.
Fig. 8.
Quantification (in percentage) of growth cone
reactions after contact with oligodendrocytes that were first raised
8-10 d in medium without PDGF and then transferred to medium
containing PDGF (A) or astrocyte-conditioned medium
(B). In C, oligodendrocytes were raised
in medium with PDGF and then transferred to medium without PDGF. Growth
cone responses were monitored 8 d after the transfer of the
oligodendrocytes. Black bars, Collapse; hatched
bars, growth around the cell; white bars, growth
across the cell. The number of growth cones is given on
top of each bar.
[View Larger Version of this Image (23K GIF file)]
Oligodendrocytes were cultured in medium containing PDGF for 1 week and
then kept in medium without PDGF for an additional 10 d to test
whether absence of PDGF would allow the permissive oligodendrocytes to
acquire their normal inhibitory properties. When DRGs were added, their
growth cones collapsed in 11 of 20 encounters and six avoided the
cells. Only three managed to cross them (Fig. 8). This indicates that
rat oligodendrocytes reacquire their inhibitory substrate properties in
the absence of PDGF.
The reappearance of inhibitory substrate properties after withdrawal of
PDGF was slow. A large proportion (60%) of oligodendrocytes that had
been raised 8 d in PDGF and then kept for an additional 6 d
in PDGF-free medium were still growth-permissive. Seventeen growth
cones crossed the cells; nine collapsed and two grew around the
cell.
Effect of glial cell-conditioned medium
It has been reported that DRG axons are not impaired in their
growth by oligodendrocytes, when these oligodendrocytes reside on type
I astrocytes (Fawcett et al., 1992 ). Because type I astrocytes are
known to produce PDGF (Richardson et al., 1988 ), we tested the effect
on oligodendrocytes of medium conditioned by glial cell cultures in
which most cells were astrocytes.
Oligodendrocytes were prepared as described in the previous
experiments, but now received conditioned medium (CM) without any
additional growth factor. After 8 d, DRGs were added. Much as with
PDGF-treated oligodendrocytes, the majority of growth cones grew onto
and over CM-treated oligodendrocytes. Eight growth cones crossed, two
avoided the cells, and only one collapsed (Fig. 8).
Thus, media conditioned by mixed glial cell cultures rich in astrocytes
alter the substrate properties of oligodendrocytes much like
recombinant PDGF-AB, and perhaps through the action of PDGF produced by
astrocytes.
DISCUSSION
The preceding results demonstrate that exposure to PDGF provokes a
marked reduction of the well known inhibitory substrate properties
(Schwab et al., 1993 ) in a significant proportion of oligodendrocytes.
It is therefore suggested that PDGF acts on regulatory pathways for the
expression of NI associated with CNS myelin and oligodendrocytes. This
suggestion is based on evaluation of oligodendrocyte substrate
properties revealed by the reaction of growth cones, and on a
quantitative assessment of immunoreactivity with antibody IN-1 against
the neurite growth inhibitory proteins (Caroni and Schwab, 1988b ).
Quantification of growth cone responses demonstrates that growing
across oligodendrocytes instead of collapsing is predominant when
oligodendrocytes have been exposed to PDGF for a certain length of
time. Otherwise, all three types of neurons used here exhibit growth
cone collapse as the typical response when their growing tip encounters
oligodendrocytes, as shown in earlier studies (Fawcett et al., 1989 ;
Bandtlow et al., 1990 ; Bastmeyer et al., 1991 ) and the present control
experiments. Because PDGF was the only component that was varied
between experimental and control cultures, the observed differences in
substrate properties of oligodendrocytes in experimental and control
cultures must result from the (direct or indirect) action of this
growth factor.
NI are potent inducers of growth cone collapse. Neutralization of these
inhibitors by the antibody IN-1 (Caroni and Schwab, 1988b ) results in a
dramatic increase in axon growth across oligodendrocytes (Bandtlow et
al., 1990 ; Bastmeyer et al., 1991 ), much as is the case with
PDGF-treated oligodendrocytes in this study. This suggests that PDGF
indeed affects the growth inhibitors most likely through interference
with their expression. This view is supported by the fact that the
intensity of IN-1 immunoreactivity was markedly decreased in
PDGF-treated oligodendrocytes. It is unlikely, although not excluded by
the present experiments, that PDGF influences the inhibitors by
modifying their structure or functional epitopes.
The reappearance of inhibitory substrate properties of PDGF-treated
oligodendrocytes after PDGF withdrawal, as evaluated by growth cone
reactions, was unusually slow. However, NI proteins are not cloned to
date, and the events on the second-messenger level responsible for the
prolonged time course of the action of PDGF on NI expression remain to
be elucidated.
We favor the view that NI, rather than other known surface molecules
with nonpermissive functions, are regulated by PDGF. First, the
similarity of axon responses to oligodendrocytes treated with IN-1
(Bandtlow et al., 1990 ; Bastmeyer et al., 1991 ) and PDGF is striking.
Second, IN-1 immunoreactivity decreases, whereas the expression of the
other putative inhibitory molecule, MAG (McKerracher et al., 1994 ;
Mukhopadhyay et al., 1994 ), remains high or even increases in
PDGF-treated oligodendrocytes. Moreover, MAG, while affecting certain
neurons including adult DRGs, does not inhibit growth of newborn rat
DRG neurons (Johnson et al., 1989 ; Bartsch et al., 1995 ), which were
used in this study. Whether MAG negatively influences the growth of
fish and Xenopus retinal ganglion cell axons has not been
tested in the relevant earlier studies, but in the present experiments,
MAG associated with oligodendrocytes did not prevent fish or
Xenopus retinal ganglion cell axons from crossing these
cells. Third, Janusin, another surface molecule potentially
contributing to the nonpermissive substrate properties of
oligodendrocytes, does not cause growth cone collapse as consistently
as the inhibitors (Taylor et al., 1993 ). Instead, purified Janusin
applied in spots to coverslips causes axons to avoid the
protein-containing regions by turning away from them. The few remaining
collapse and avoidance responses seen with IN-1-treated and
PDGF-treated oligodendrocytes, however, could perhaps be attributed to
these or other molecules, or to incomplete abolition of the
inhibitors.
Because oligodendrocytes exhibit their inhibitory properties after
differentiation to highly branched, O1/GalC-expressing cells, care was
taken to monitor only growth cone contacts with differentiated cells.
In both PDGF-treated and untreated glial cultures, the vast majority of
oligodendrocytes were indeed O1/GalC-positive at the time of the
recordings. Also, none of the cells under consideration had arisen
recently through proliferation of progenitors. This was demonstrated by
experiments with the cytostatic drug AraC, which prevented the
development of new oligodendrocytes from dividing precursor cells, and
by BrdU incorporation assays. More importantly, labeling of
oligodendrocytes with specific antibodies against advanced myelin
marker proteins confirmed that PDGF had not prevented differentiation
and myelin protein expression in these glial cells. Thus, the low
proportion of inhibitory oligodendrocytes in PDGF-treated cultures is
not attributable to incomplete differentiation of the cells or to
continued generation of ``young'' oligodendrocytes from proliferating
precursors. Moreover, differentiated oligodendrocytes, the majority of
which caused growth cone collapse in controls, had lost their
inhibitory properties after 8-10 d in PDGF-containing medium. This
substantiates the suggestion that PDGF causes a downregulation of the
NI in mature oligodendrocytes, and that PDGF withdrawal has the
opposite effect.
Another possibility that could also account for the increase in axon
growth across oligodendrocytes is an abnormal distribution of NI in
PDGF-treated oligodendrocytes, such that the cells fail to translocate
the NI proteins to their membraneous extensions. This is derived from
the observation that IN-1 immunofluorescence was present in the cell
bodies and soma near processes of PDGF-treated oligodendrocytes. Most
of this fluorescence, however, represents an artifact caused from
autofluorescence and by the immunostaining procedure with the
Cy-3-conjugated secondary antibodies. Still, both views, downregulation
of the expression or prevention of the normal distribution of NI, are
compatible with the outcome of the present functional assays.
Because mAb IN-1 does not reliably recognize its antigen in immunoblots
(producing more than 20 bands) and probes for in situ
hybridization are not available, more specific tests of NI expression
in PDGF-treated and untreated oligodendrocytes cannot be performed at
present.
The observation that conditioned media had similar effects as
recombinant PDGF on the increase in permissiveness of oligodendrocytes
is interesting in light of earlier findings. There was no inhibition of
axon growth in complex glial cultures in which oligodendrocytes resided
on beds of astrocytes (Fawcett et al., 1992 ). With the notion that
astrocytes secrete PDGF (Richardson et al., 1988 ; Pringle et al.,
1989 ), this very growth factor may have affected the normal expression
of inhibitors on these oligodendrocytes. Our attempts to deplete media
of PDGF in such cultures using commercially available PDGF antibodies
failed, so a direct test of the above speculation is missing.
Influences of PDGF on oligodendrocytes requires the presence of PDGF
receptors, which are known to activate intracellular signaling cascades
and gene expression (Rozengurt, 1986 ; Hart et al., 1989a ). It has
been demonstrated that oligodendrocyte precursors express PDGF
receptors of the -subtype (Hart et al., 1989b ; McKinnon et al.,
1990 ). Using the relevant antibodies (kindly provided by M. Paech,
Roche, Basel, Switzerland), we were able to confirm the presence of
-receptors on oligodendrocyte precursors; they were not detected on
differentiating oligodendrocytes whether treated with PDGF or not (D. Lang and M. Hille, unpublished observations). PDGF -receptors are
activated by all three forms of PDGF, PDGF-AA, PDGF-BB, and PDGF-AB
(Barres et al., 1993 ), the last of which was the form used in this
study.
PDGF (all forms) was shown to promote proliferation of precursors
(Noble et al., 1988 ; Richardson et al., 1988 ), and PDGF-AA supports
their survival, but lower concentrations are needed for the survival
effect (Barres et al., 1993 ). From this dual effect it was proposed
that more than one type of receptor and diverse signaling cascades are
involved (Barres et al., 1993 ). These two effects were proposed to be
evoked by PDGF -receptors and by a receptor that remains to be
identified. Survival of oligodendrocytes was suggested to be promoted
by this novel receptor type (Barres et al., 1993 ).
Whether the effect of PDGF-AB on oligodendrocyte substrate properties
seen here rests on the activation of the receptor that promotes
survival is unknown. The PDGF effects noted in the present study,
together with the beneficial effect of PDGF described earlier (Grinspan
et al., 1993 ) on increased production of mRNAs for myelin marker
proteins, speaks for a more long-lasting presence of the relevant PDGF
receptor or mediation of the effects through pathways that do not
depend on PDGF receptors.
Whether PDGF would have beneficial effects on axonal regeneration
in vivo is not known. One might assume that after CNS
injury, blood platelets release PDGF in large quantities, which might
render oligodendrocytes near the lesion site permissive for axonal
regrowth. However, inhibitors associated with myelin (Schwab and
Caroni, 1988 ) in these regions may persist and continue to exert their
negative effects on regrowing axons. Still, to our knowledge this is
the first account of the regulation of oligodendrocyte inhibitors, and
this may allow assessment of regulatory pathways.
FOOTNOTES
Received May 7, 1996; revised June 21, 1996; accepted June 28, 1996.
This work was supported by Deutsche Forschungsgemeinschaft Grant
Stu112/10 to C.A.O.S. and the Gemeinnützige
Hertie-Stiftung. D.M.L. is a fellow of the Boehringer-Ingelheim Fonds.
We thank Drs. M. Bastmeyer, C. Erxleben, and J. Ostheim for help with
the image processing system. Mary Ann Cahill corrected the English.
Correspondence should be addressed to Claudia A. O. Stuermer, Faculty
of Biology, University of Konstanz, D-78434 Konstanz,
Germany.
REFERENCES
-
Bandtlow C,
Zachleder T,
Schwab ME
(1990)
Oligodendrocytes arrest neurite growth by contact
inhibition.
J Neurosci
10:3837-3848 .
[Abstract]
-
Barres BA,
Schmid R,
Sendtner M,
Raff MC
(1993)
Multiple
extracellular signals are required for long-term oligodendrocyte
survival.
Development
118:283-295 .
[Abstract]
-
Bartsch U,
Bandtlow CE,
Schnell L,
Bartsch S,
Spillmann AA,
Rubin BP,
Hillenbrandt R,
Montag D,
Schwab ME,
Schachner M
(1995)
Lack
of evidence that myelin-associated glycoprotein is a major inhibitor of
axonal regeneration in the CNS.
Neuron
15:1375-1381.
[ISI][Medline]
-
Bastmeyer M,
Beckmann M,
Schwab ME,
Stuermer CAO
(1991)
Growth of regenerating goldfish axons is inhibited
by rat oligodendrocytes and CNS myelin but not by goldfish optic nerve
tract oligodendrocyte-like cells and fish CNS myelin.
J Neurosci
11:626-640 .
[Abstract]
-
Bastmeyer M,
Bähr M,
Stuermer CAO
(1993)
Fish optic
nerve oligodendrocytes support axonal regeneration of fish and
mammalian retinal ganglion cells.
Glia
8:1-12 .
[ISI][Medline]
-
Caroni P,
Schwab ME
(1988a)
Two membrane protein fractions
from rat central myelin with inhibitory properties for neurite growth
and fibroblast spreading.
J Cell Biol
106:1281-1288 .
[Abstract/Free Full Text]
-
Caroni P,
Schwab ME
(1988b)
Antibody against
myelin-associated inhibitor of neurite growth neutralizes nonpermissive
substrate properties of CNS white matter.
Neuron
1:85-96 .
[ISI][Medline]
-
Fawcett JW,
Rokos J,
Bakst I
(1989)
Oligodendrocytes repel
axons and cause axonal growth cone collapse.
J Cell Sci
92:93-100 .
[Abstract/Free Full Text]
-
Fawcett JW,
Fersht N,
Housden L,
Schachner M,
Pesheva P
(1992)
Axonal growth on astrocytes is not inhibited by
oligodendrocytes.
J Cell Sci
103:571-579 .
[Abstract]
-
Grinspan J,
Wrabetz L,
Kamholz J
(1993)
Oligodendrocyte
maturation and myelin gene expression in PDGF-treated cultures from rat
cerebral white matter.
J Neurocytol
22:322-333 .
[ISI][Medline]
-
Hart IK,
Richardson WD,
Bolsover SR,
Raff MC
(1989a)
PDGF and
intracellular signaling in the timing of oligodendrocyte
differentiation.
J Cell Biol
109:3411-3417 .
[Abstract/Free Full Text]
-
Hart IK,
Richardson WD,
Heldin CH,
Westermark B,
Raff MC
(1989b)
PDGF receptors on cells of the
oligodendrocyte-type-2 astrocyte (O-2A) cell lineage.
Development
105:595-603 .
[Abstract/Free Full Text]
-
Heldin CH,
Backstrom G,
Ostman A,
Hammacher A,
Ronnstrand L,
Rubin K,
Nister M,
Westermark B
(1988)
Binding of different dimeric
forms of PDGF to human fibroblasts: evidence for two separate receptor
types.
EMBO J
7:1387-1393 .
[ISI][Medline]
-
Johnson PW,
Abramow-Newerly W,
Seilheimer B,
Sadoul R,
Tropak MB,
Arquint M,
Dunn RJ,
Schachner M,
Roder JC
(1989)
Recombinant
myelin-associated glycoprotein confers neural adhesion and neurite
outgrowth function.
Neuron
3:377-385 .
[ISI][Medline]
-
Lang DM,
Rubin BP,
Schwab ME,
Stuermer CAO
(1995)
CNS myelin
and oligodendrocytes of the Xenopus spinal cord
but not optic
nerve are nonpermissive for axon growth.
J Neurosci
15:99-109 .
[Abstract]
-
McCarthy KD,
De Vellis J
(1980)
Preparation of separate
astrocyte and oligodendrocyte cultures from rat cerebral tissue.
J Cell Biol
85:890-902 .
[Abstract/Free Full Text]
-
McKerracher L,
David S,
Jackson DL,
Kottis V,
Dunn RJ,
Braun PE
(1994)
Identification of myelin-associated glycoprotein as
a major myelin-derived inhibitor of neurite growth.
Neuron
13:805-811 .
[ISI][Medline]
-
McKinnon RD,
Matsui T,
Dubois-Dalcq M,
Aaronson SA
(1990)
FGF
modulates the PDGF-driven pathway of oligodendrocyte development.
Neuron
5:603-614 .
[ISI][Medline]
-
Mukhopadhyay G,
Doherty P,
Walsh FS,
Crocker PR,
Filbin MT
(1994)
A novel role for myelin-associated glycoprotein as
an inhibitor of axonal regeneration.
Neuron
13:757-767 .
[ISI][Medline]
-
Noble M,
Murray K,
Stroobant P,
Waterfield MD,
Riddle P
(1988)
Platelet-derived growth factor promotes division and
motility and inhibits premature differentiation of the
oligodendrocyte/type-2 astrocyte progenitor cell.
Nature
333:560-565 .
[Medline]
-
Nowakowski RS,
Lewin B,
Miller MW
(1989)
Bromodeoxyuridine
immunohistochemical determination of the length of the cell cycle and
the DNA-synthetic phase for an anatomically defined population.
J Neurocytol
18:311-318 .
[ISI][Medline]
-
Pringle N,
Collarini EJ,
Mosle MJ,
Heldin CH,
Westermark B,
Richardson WD
(1989)
PDGF A chain homodimers drive proliferation of
bipotential (O-2A) glial progenitor cells in the developing rat optic
nerve.
EMBO J
8:1049-1056 .
[ISI][Medline]
-
Raff M,
Miller RH,
Noble M
(1983)
A glial progenitor cell
that develops in vitro into an astrocyte or an oligodendrocyte
depending on culture medium.
Nature
303:390-396 .
[Medline]
-
Raff MC,
Abney E,
Fok-Seang J
(1985)
Reconstitution of a
developmental clock in vitro: a critical role for astrocytes in the
timing of oligodendrocyte differentiation.
Cell
42:61-69 .
[ISI][Medline]
-
Ranscht B,
Clapshaw PA,
Price J,
Noble M,
Seifert W
(1982)
Development of oligodendrocytes and Schwann cells
studied with a monoclonal antibody against galactocerebroside.
Proc Natl Acad Sci USA
7:2709-2713.
-
Richardson WD,
Pringle N,
Mosley MJ,
Westermark B,
Dubois-Dalcq M
(1988)
A role for platelet-derived growth factor in normal
gliogenesis in the central nervous system.
Cell
53:309-319 .
[ISI][Medline]
-
Rozengurt E
(1986)
Early signals in the mitogenic response.
Science
234:161-166 .
[Abstract/Free Full Text]
-
Schnell L,
Schneider R,
Kolbeck R,
Barde Y-A,
Schwab ME
(1994)
Neurotrophin-3 enhances sprouting of corticospinal
tract during development and after adult spinal cord lesion.
Nature
367:170-173 .
[Medline]
-
Schwab ME,
Caroni P
(1988)
Oligodendrocytes and CNS myelin
are nonpermissive substrates for neurite growth and fibroblast
spreading in vitro.
J Neurosci
8:2381-2393 .
[Abstract]
-
Schwab ME,
Kapfhammer J,
Bandtlow CE
(1993)
Inhibitors of
neurite growth.
Annu Rev Neurosci
16:565-595 .
[ISI][Medline]
-
Sommer I,
Schachner M
(1981)
Monoclonal antibodies (O1 to O4)
to oligodendrocyte cell surfaces. An immunocytological study in the
central nervous system.
Dev Biol
83:311-327 .
[ISI][Medline]
-
Taylor J,
Pesheva P,
Schachner M
(1993)
Influence of janusin
and tenascin on growth cone behavior in vitro.
J Neurosci Res
35:347-362 .
[ISI][Medline]
This article has been cited by other articles:

|
 |

|
 |
 
C. A.O. Stuermer, D. M. Lang, F. Kirsch, M. Wiechers, S.-O. Deininger, and H. Plattner
Glycosylphosphatidyl Inositol-anchored Proteins and fyn Kinase Assemble in Noncaveolar Plasma Membrane Microdomains Defined by Reggie-1 and -2
Mol. Biol. Cell,
October 1, 2001;
12(10):
3031 - 3045.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|